R&D Trends

Helsinn grants Especificos Stendhal rights to anamorelin for cachexia-anorexia in NSCLC

Wednesday, January 30, 2013 09:13 AM

Helsinn Group, a privately owned pharmaceutical group based in Switzerland, has granted Especificos Stendhal, a Latin American specialty company, exclusive commercialization rights for Mexico, Venezuela, Colombia, Perú, Ecuador and most of Central American countries, to this novel ghrelin receptor agonist.

More... »

U.K. clinical trials database first major output for Cell Therapy Catapult

Friday, January 18, 2013 01:52 PM

The Cell Therapy Catapult, focused on the development of the U.K. cell therapy industry to increase the nation's health and wealth, has published its database of ongoing clinical trials in this area in the U.K.

More... »

Covance launches five-year collaboration on early clinical research

Friday, January 18, 2013 01:23 PM

Global CRO Covance and the Royal Liverpool and Broadgreen University Hospitals NHS Trust have entered into a five-year exclusive agreement to work together in conducting early clinical trials at the Royal Liverpool University Hospital on behalf of biotechnology and pharmaceutical companies.

More... »

Versartis closes $25M Series C financing

Wednesday, January 16, 2013 10:24 AM

Versartis, an emerging biotechnology company focused on endocrine disorders, has completed a $25 million Series C financing lead by new investor Aisling Capital. The primary use of the proceeds will be to fund clinical trials of its lead product, VRS-317, for growth hormone deficiency (GHD) in pediatric patients. VRS-317 is a proprietary once monthly form of recombinant human growth hormone (rhGH).

More... »

PatientsLikeMe, AKU Society to develop first open registry for alkaptonuria patients

Monday, January 14, 2013 01:52 PM

PatientsLikeMe, a patient network that helps improve lives and a real-time research platform that advances medicine, and the AKU Society, which helps patients with alkaptonuria (AKU), raises awareness and supports research into its treatment, are working together to create the first open, global registry for patients with AKU, one of the world's rarest diseases and the first genetic disease discovered.

More... »

GVK Biosciences, Onconova partner to advance new cancer drugs

Monday, January 14, 2013 01:23 PM

GVK Biosciences, a contract research and development organization, has entered into a novel joint partnership with Onconova Therapeutics, a Newtown, Penn.-based biopharmaceutical company focused on novel small molecules for oncology, to develop new drugs for cancer.

More... »

Horizon, Boehringer Ingelheim enter oncology research service collaboration

Monday, January 14, 2013 11:36 AM

Horizon Discovery, a provider of research tools to support the development of personalized medicines has signed a research service collaboration agreement with Germany-based Boehringer Ingelheim.

More... »

BioCrossroads Indiana Seed Fund II makes first investments in start-ups

Friday, January 11, 2013 02:42 PM

BioCrossroads Indiana Seed Fund II, an $8.25 million early-stage fund focused on identifying, creating and developing the next generation of leading Indiana-based life sciences companies, has made its first two investments: Esanex, a company developing an oncology drug, and Algaeon, which has developed an algae cultivation technology for use in the nutraceutical and micronutrient markets. 

More... »

Altravax awarded $1.2M to advance dengue vaccine and hep B therapeutic

Friday, January 11, 2013 11:13 AM

Altravax, a privately held biopharmaceutical company based in Fargo, N.D., has been awarded two Advanced Technology Small Business Innovation Research grants from the NIH's National Institute of Allergy and Infectious Diseases for research on vaccines to prevent infection by dengue virus and to treat chronic hepatitis B. Each of these viruses is a global problem and the focus of Altravax's two lead commercial programs.

More... »

Priaxon, GSK collaborate on PPIs

Wednesday, January 9, 2013 11:39 AM

Priaxon, an emerging pharmaceutical company based in Germany, has formed a collaboration with GlaxoSmithKline (GSK) to research and develop small molecule modulators of protein-protein-interactions.

More... »